9 Mar 2016 15:33
Premaitha Health plc
("Premaitha" or the "Company")
Holding in Company, Orderly Market Undertaking, Directors' Dealings and Concert Party Disclosure
Manchester, UK - 9 March 2016: Premaitha Health plc (AIM: NIPT), the company enabling wide scale adoption of a safe, fast, accurate and complete CE-marked, non-invasive prenatal screening system, announces that it has received the following notification of disposals of shares from certain significant shareholders at a price of 8 pence per share:
Shareholder | Number of shares disposed of | Resultant shareholding
| % of Company's issued share capital |
Animatrix Capital LLP | 21,858,754 | - | - |
Loxbridge Research LLP | 3,141,246 | 9,284,264 | 4.1% |
|
|
|
|
Total | 25,000,000 | 9,284,264 | 4.1% |
The 25,000,000 ordinary shares have been placed by the Company's joint broker, finnCap, to certain new and existing institutional investors and to certain directors of the Company. Following this placing of shares, the issued share capital of the Company remains unchanged at 228,163,709 ordinary shares of 10 pence each.
Orderly Market Undertaking
Rupert Lywood is a founder and an ultimate beneficial owner of Animatrix Capital LLP ("Animatrix"), which holds significant interests in Zoragen Biotechnologies LLP ("Zoragen") and Loxbridge Research LLP ("Loxbridge").
Following the disposal of shares detailed above, Mr Lywood, Zoragen and Loxbridge have an aggregate interest over 10,204,374 shares in the Company, representing approximately 17.9 per cent. of the Company's issued share capital.
Mr Lywood has confirmed to the Company and finnCap, as joint broker to the Company, that neither he, Zoragen nor Loxbridge will dispose of any ordinary shares in the Company for a period of six months from 9 March 2016, unless finnCap, acting as the Company's joint broker, bids for such ordinary shares pursuant to market demand.
Directors' Dealings
Stephen Little and Adam Reynolds, who are directors of the Company, have both acquired shares at a price of 8 pence per share as set out in the table below:
Director | Number of shares acquired | Resultant shareholding | % of Company's issued share capital |
|
|
|
|
Stephen Little | 700,000 | 3,472,727 | 1.5% |
Adam Reynolds | 500,000 | 3,301,137 | 1.4% |
Concert Party Disclosure
Following the trading of shares as detailed above, the shareholdings of members of the concert party in the Company are as follows:
Shareholding | % | Number of options held | Maximum potential shareholding
| % | |
Zoragen Biotechnologies LLP | 29,373,230 | 12.9% | - | 29,373,230 | 11.7% |
Animatrix Capital LLP | - | - | - | - | - |
Loxbridge Research LLP | 9,284,264 | 4.1% | - | 9,284,264 | 3.7% |
Rupert Lywood | 2,160,000 | 0.9% | - | 2,160,000 | 0.9% |
Stuart Lawson | - | - | - | - | - |
Charles Roberts | 6,339,546 | 2.8% | - | 6,339,546 | 2.5% |
David Evans | 3,540,636 | 1.6% | - | 3,540,636 | 1.4% |
Stephen Little* | 3,472,727 | 1.5% | 10,555,984 | 14,028,711 | 5.3% |
Peter Collins | 3,522,727 | 1.5% | 5,638,174 | 9,160,901 | 3.6% |
William Denman | 250,000 | 0.1% | 2,654,989 | 2,904,989 | 1.2% |
Michael Risley | 15,000 | 0.0% | 2,654,989 | 2,669,989 | 1.1% |
Rachel Shelmerdine | 15,000 | 0.0% | 1,055,598 | 1,070,598 | 0.4% |
NWF | 4,545,455 | 2.0% | - | 4,545,455 | 1.8% |
Adam Reynolds | 3,301,137 | 1.4% | 591,666 | 3,892,803 | 1.5% |
Total | 65,819,722 | 28.8% | 23,151,400 | 88,971,122 | 35.4% |
* In addition to the options set out above (all of which were subject to the waiver of the obligations of Rule 9 of the Takeover Code ("Rule 9") at the time of the Company's admission to AIM in July 2014), Stephen Little holds an additional 1,500,000 options (as announced on 15 July 2015) that have not been waived from the obligations of Rule 9.
For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 6865 |
Dr Stephen Little, Chief Executive Office |
|
Joanne Cross, Head of Marketing |
|
investors@premaitha.com |
|
|
|
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | Tel: +44 (0) 20 7886 2500 |
Robert Naylor (Corporate Finance) / Maisie Rose Atkinson (Sales) |
|
|
|
finnCap (Joint Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) |
|
Tony Quirke (Corporate Broking) |
|
|
|
Vigo Communications | Tel: +44 (0) 20 7830 9700 |
Ben Simons / Fiona Henson |
|
premaitha@vigocomms.com |
|
About Premaitha
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its speed and high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures which carry a risk of miscarriage.
NIPT is an emerging, multi-billion dollar global market and Premaitha's complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.